Fast Market Research announces the availability of the new Global Markets Direct report, "Transcription Factor AP 1 - Pipeline Review, H2 2016", on their comprehensive research portal

Boston, MA -- (SBWire) -- 02/21/2017 --Global Markets Direct's, 'Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Pipeline Review, H2 2016', provides in depth analysis on Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted pipeline therapeutics.

The report provides comprehensive information on the Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics development and features dormant and discontinued projects.

Get More Details on this Report and a Full Table of Contents at Transcription Factor AP 1 - Pipeline Review, H2 2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Report Scope

-The report provides a snapshot of the global therapeutic landscape for Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN)

-The report reviews Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics and enlists all their major and minor projects

-The report assesses Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics

Reasons to Get this Report

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN)

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:
-Fibroblast Growth Factor Receptor 1 - Pipeline Review, H2 2016
-Cyclin Dependent Kinase 7 - Pipeline Review, H2 2016
-Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016
-Insulin Like Growth Factor 1 Receptor - Pipeline Review, H2 2016
-Fibroblast Growth Factor Receptor 2 - Pipeline Review, H2 2016